Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8649740

Ewing's sarcoma.

R Vlasak·F H Sim
View original source ↗Export metadata ↓

Abstract

Ewing's sarcoma is the second most common primary malignant bone tumor of children. Tremendous strides in the multidisciplinary treatment of Ewing's sarcoma have been made over the past 25 years. Aggressive chemotherapy has increased the 5-year survival rates from 10% to over 70%. The role of surgery for local control has gained importance. These advances in the diagnosis, staging, and treatment of Ewing's sarcoma are discussed in detail.

Explore related subjects

Bone NeoplasmsChildHumansNeoplasm StagingPrognosisSarcoma, EwingJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Vlasak, F H Sim. 1996. Ewing's sarcoma.. https://pubmed.ncbi.nlm.nih.gov/8649740/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma?

BACKGROUND: The utility of performing whole-body bone scintigraphy (BS) as part of a routine staging workup for patients with renal cell carcinoma (RCC) is currently being debated. This study investigated the diagnostic performance of BS in 36 patients with a high pretest probability for bone metastases due to abnormal laboratory tests, pain, or confirmed nonosseous metastases. METHODS: Planar whole-body BS was performed in all patients 3 hours after the intravenous injection of 555 MBq (15 mCi) of technetium-99m-3,3-diphosphono-1,2-propane dicarboxylic acid tetrasodium salt). RESULTS: In 14 of 36 patients, bone metastases could be confirmed either due to computed tomography or magnetic resonance imaging (n=11) or open site directed biopsy (n=3), respectively. The sensitivity ranged from 10% to 60%, depending on the applied visual threshold. The extent of the metastatic involvement was underestimated in all cases. No diagnostic pattern of tracer accumulation, clinical features, or laboratory tests was identified as enhancing the sensitivity for the detection of bone metastases in this population. CONCLUSIONS: The authors concluded that, even among preselected patients, BS has no diagnostic role in RCC and should therefore be omitted from the clinical workup.

Bone Neoplasms↗